logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences PLC's chairman discusses the potential for its 'crown jewel' Foralumab drug

Tiziana Life Sciences PLC's (LON:TILS)(NASDAQ:TLSA) chairman Gabriele Cerrone tells Proactive London's Andrew Scott why he feels its drug Foralumab is the 'crown jewel' in the company's portfolio.

It's a fully-human monoclonal anti-CD3 antibody which is being developed for treatment of inflammatory and autoimmune diseases.

Cerrone says the drug potentially addresses by far the largest markets of any of the drugs in its pipeline.

Tiziana's looking to launch Phase II trials in Crohn's Disease and MS around the end of June or early July and Cerrone says that'll put them on the path to once and for all seeing whether one of these two indications has efficacy.

''The potential turnover you can have for a monoclonal antibody is multi-billions per indication'', he says.

Quick facts: Tiziana Life Sciences PLC

Price: 110 GBX

AIM:TILS
Market: AIM
Market Cap: £182.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 lower as US infections continue to rise

Headlines from the Proactive UK newsroom. The FTSE 100 headed lower in an uncertain start to the week as investors worried over the surge in US COVID-19 infections. The blue-chip index dipped 24 to 6,135. Deliveroo’s boss has warned that restaurants are 'hurting' due to the coronavirus...

5 days, 14 hours ago

2 min read